Gene therapy
Gene therapy is a medical approach that treats or aims to cure disease by changing gene expression, adding genetic material, editing DNA, or modifying a patient's cells so they produce a therapeutic effect.
What gene therapy is
Gene therapy is a treatment strategy that uses genetic material or genetically modified cells to change how disease-related cells behave. The goal may be to replace a missing function, silence a harmful gene, add a useful gene, edit a DNA sequence, or give immune cells new abilities. It is most often discussed for inherited disorders, cancers, and a growing set of rare diseases.
How it can work
Gene therapies do not all use the same mechanism. Some add a working copy of a gene so cells can make a needed protein. Some turn down or disable a harmful gene. Some use genome editing to make a targeted DNA change. Others modify a patient's own cells outside the body and return them with new therapeutic properties. The right approach depends on the disease, target tissue, cell type, and risk profile.
Vectors and delivery
A vector is a delivery vehicle for genetic material. Many gene therapies use modified viruses because viruses naturally enter cells, but the vectors are engineered so they cannot cause the original infectious disease. Nonviral methods, such as lipid particles or plasmid DNA, are also used or studied. Delivery is one of the hardest parts: the therapy has to reach enough of the right cells while avoiding harmful effects in other tissues.
In vivo and ex vivo therapy
In vivo gene therapy delivers the genetic tool directly into the body, often by injection into the bloodstream, eye, muscle, or another target site. Ex vivo therapy removes cells from a patient, modifies them in a lab, tests or expands them, and then returns them. CAR T cell therapies for some cancers are a well-known ex vivo example because a patient's immune cells are engineered to recognize cancer targets.
Diseases and current use
Approved cellular and gene therapy products now exist for selected cancers, inherited blood disorders, inherited retinal disease, spinal muscular atrophy, hemophilia, Duchenne muscular dystrophy, certain metabolic and immune disorders, and other narrow indications. The approved list changes as regulators review new evidence, so a patient-specific question should be answered from current regulatory labels and a specialist's guidance, not from a general article.
Safety and follow-up
Gene therapy can have serious risks. Possible problems include immune reactions, inflammation, liver toxicity, insertional mutagenesis, off-target editing, uneven expression, loss of effect over time, and unexpected long-term effects. Because some treatments may persist in the body, regulators often require careful manufacturing controls, clinical monitoring, and long-term follow-up after treatment.
Manufacturing and access
Gene therapies can be difficult to make. Some are customized from a patient's own cells, while others require high-quality viral-vector production, specialized testing, cold-chain logistics, and treatment centers with trained teams. These steps help protect safety and consistency, but they also contribute to high prices and uneven access. Manufacturing capacity and reimbursement are part of the science-to-care problem.
Why it matters
Gene therapy matters because it can treat disease closer to its biological cause than many conventional medicines. For some conditions, a single treatment may produce long-lasting benefit. The same power makes the field ethically and clinically demanding: patients need realistic expectations, transparent evidence, long-term safety tracking, fair access, and careful limits around uses that could affect future generations.